A randomized, open-label, multiple dose, four-way crossover pharmacodynamic equivalence study comparingOrlistat 60mg and 120mg hard gelatin capsules in healthyvolunteers.
- Registration Number
- CTRI/2011/12/002292
- Lead Sponsor
- aboratorios Liconsa SA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 60
1. Healthy Caucasian subjects, males or females >=18 to <=55 years old on the .
day of screening
2. If females: subjects who are willing to use tampon during menstruation
3. Informed Consent Form signed and dated prior to screening procedures.
4. BMI >=25.00 to <=30.00 kg/m2 (the minimum body weight for male subjects must be 70 kg, for female subjects - 60 kg)
5. Physical examination without any clinically relevant abnormality
6. No clinically relevant abnormal laboratory values (as per Annexure 2)
7. Subject who accepts the possible weight loss (approximately 10% change from the baseline)
8. Subjects who are willing to fast overnight each day and consume the repetitively provided standard meals during the whole study
9. Subject able and willing to understand and follow study related procedures
1. Known allergy or hypersensitivity to orlistat or its derivatives and/or to any study product excipients
2. Any known significant current or past acute or chronic disease or condition of the: circulatory system, respiratory system, hematopoietic system, alimentary tract, urinary tract, endocrine system, nervous system, musculoskeletal system, an allergic disease (excluding allergic rhinitis), genetic disorder or psychiatric disorder that could influence the present general health condition, at the Investigators discretion
3. Current disease of the alimentary tract, liver or kidneys that may influence
absorption, distribution and/or elimination of the studied drugs, as assessed by the Investigator and documented in the medical history
4. Current disease of gall bladder and/or cholelithiasis
5. The malabsorption syndrome in medical history
6. Pancreatitis and/or nephrolithiasis in medical history
7. Constipation and/or diarrhea within 1 week before the screening
8. Participation in other clinical trials, where at least one dose of study drug was administered, within 30 days preceding the screening
9. Blood loss or donation exceeding 300 mL within 4 weeks preceding the screening
10. Bradycardia 50 bpm at screening and on day O
11. Tachycardia 100bpm at screening and on day O
12. Blood pressure: systolic 140mmHg or 90mmHg, diastolic 60 mmHg or 90 mmHg at screening and on day O.
13. Body temperature: 36,0°C or 37,5°C on the day of screening and on Day O
14. Abnormal clinical laboratory results assessed by Investigator as clinically relevant (CR)
15. Positive results of HbsAg and/or anti-HCV and/or anti-HIV tests
16. Positive result of stool culture test against Salmonellal Shigella
17. Positive result of the stool ova, cysts & parasites (OCP) test
18. Clinically relevant abnormalities in ECG recording on the day of screening
19. Clinically relevant abnormalities in abdominal USG at screening
20. Current or ex-smoker or tobacco user who has stopped smoking less than six (6) months before screening
21. Pregnant, breast-feeding females
22. History of drug and/or alcohol dependence
23. Subjects who adhere to a special diet (e.g. vegetarian, protein, raw food, etc.) within 30 days preceding day 1 in run out period
24. of the Administration of drugs which may have an influence subjects condition or study results within 4 weeks preceding the first study drug administration. Only the drugs in dose assessed by the Investigator as safe and not having an impact on the study results are allowed within this time (e.g. paracetamol,
vitamins)
25. Ingestion of laxatives and/or fat-blocking nutritional supplements within 14 days preceding day 1 in run-in period
26. Positive drug screen or alcohol breath test on day 0
27. Alcohol consumption within 96 hours preceding day 1 in run-in period
28. Consumption of beverages containing caffeine or other methylxanthines (tea, coffee, cola, chocolate, cocoa, energy drinks) in excessive amount (Le. more than 1 liter daily)
29. Any reason the subject is considered by the investigator to be an unsuitable candidate to participate in the study
Study & Design
- Study Type
- BA/BE
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method